Clinical Trials · NCT01572753
Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 161
- Start date
- Apr 2012
- Locations
- 1 site, Germany
- Primary endpoint
- AUC 0-24h; Area under the semaglutide concentration curve from time 0-24 hours after the 10th dosing